Kynexis extends Series A to EUR 97 million, Novartis Venture Fund joins round led by Forbion
PUBT · 1d ago
Share
Listen to the news
- Kynexis, a clinical-stage biotech focused on treatments to improve cognition in brain diseases, raised a €40 million Series A extension.
- Total Series A financing reached €97 million, with Novartis Venture Fund leading the extension round.
- Forbion Capital Partners Management Services BV participated alongside existing investors Ysios Capital and Sunstone Life Science Ventures.
- Proceeds target Phase 2 close-out work for KYN-5356 in cognitive impairment associated with schizophrenia, with preparation for registrational studies.
- Kynexis expects topline results from the Phase 2 proof-of-concept study by end-2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forbion Capital Partners Management Services BV published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending